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Abstract
Activin is known to play an important regulatory role in reproduction, including pregnancy. To
further examine the role and signaling mechanism of activin in regulating placental function, the
steady-state level of activin type I receptor (ActRI) mRNA in immortalized extravillous
trophoblasts (IEVT) cells was measured using competitive PCR (cPCR). An internal standard of
ActRI cDNA for cPCR was constructed for the quantification of ActRI mRNA levels in IEVT cells.
ActRI mRNA levels were increased in a dose-dependent manner by activin-A with the maximal
effect observed at the dose of 10 ng/ml. Time course studies revealed that activin-A had maximal
effects on ActRI mRNA levels at 6 hours after treatment. The effects of activin-A on ActRI mRNA
levels was blocked by follistatin, an activin binding protein, in a dose-dependent manner. In addition,
inhibin-A inhibited basal, as well as activin-A-induced ActRI mRNA levels. These findings provide
evidence, for the first time, that activin-A modulates ActRI mRNA levels in human trophoblast cells.
Introduction
Although activins and inhibins were originally isolated
from follicular fluids and identified as stimulators and in-
hibitors, respectively, of pituitary follicle-stimulating hor-
mone (FSH), the identification of inhibins and activins in
a wide variety of tissues suggest that these factors play
much greater roles than the control of FSH secretion [1–
5]. Also, it has become evident that these factors exert
their effects mostly in autocrine/paracrine manners.
Similar to other members of the transforming growth fac-
tor-β (TGF-β) family, activins exert their actions by inter-
acting with both type I and type II membrane serine/
threonine kinase receptors [6,7]. Two type I (ActRI and Ac-
tRIB) and two type II (ActRII and ActRIIB) receptors have
been shown to interact with activins [5] and their mRNAs
have been detected in human placental trophoblast cells
[8–10], as well as in choriocarcinoma cells [11]. Activins,
particularly activin-A, has been shown to be produced by
human placenta [5,11–13]. Many studies have demon-
strated that activin-A plays important regulatory roles in
human placenta, including stimulation of cytotrophob-
last differentiation into invasive extravillous cytotrophob-
last [14]; stimulation of progesterone [11,14–16], human
chorionic gonadotropin (hCG)[15,17,18], estradiol [11],
gonadotropin-releasing hormone (GnRH) [15] and oxy-
tocin [19] secretion. However, regulation of activin sign-
aling at the receptor level has not been examined.
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The human placenta provides specialized functions dur-
ing gestation that is critical for the development of the em-
bryo and fetus. Among these important functions are the
production of hormones, cytokines and growth factors
that contribute to the gestational coordination of mater-
nal, extraembryonic, and embryonic tissues. Develop-
ment of the human placenta depends on proliferation
and differentiation of certain trophoblast cells as well as
invasion to the endometrium and its vasculature by a
highly proliferative, migratory and invasive subpopula-
tion of extravillous trophoblast (EVT) cells [20].
To further study activin signaling in human placenta, we
have developed a competitive quantitative PCR to meas-
ure ActRI mRNA levels in an immortalized EVT cell line,
HTR8/SVneo. We report here the first evidence that ac-
tivin-A regulates its own receptor mRNA levels in a dose-
and time-dependent manner and this effect can be
blocked by its binding protein, follistatin, or its antago-
nist, inhibin-A in human placenta.
Materials and Methods
Cell line
The use of placental tissue samples and cell lines was ap-
proved by the Clinical Screening Committee for Research
and Other Studies Involving Human Subjects, University
of British Columbia. The HTR-8/SVneo trophoblast cell
line was generously provided by Dr. PK Lala (University of
Western Ontario). This cell line was obtained from hu-
man first trimester placenta explant cultures and immor-
talized using SV40 large T antigen [21]. Cells were
cultured in RPMI 1640 medium containing 10% FBS and
antibiotics (Invitrogen Canada Inc., Burlinton, ON) as
previously described [21].
PCR Primers
Oligonucleotide primers were synthesized based on the
published sequences of the human ActRI [22], and β-actin
[23]. The upstream primer (ActRI-1), 5'-GATGAGAAGT-
CATGGTTCAGG-3', and downstream primer (ActRI-2),
5'-TATGTTTGGCCTTTGTTGATC-3' were designed such
that the predicted sizes of PCR products are 700 bp for na-
tive ActRI cDNA. Primers are chosen to flank introns so
that the amplified ActRI cDNA is readily distinguished
from a possible contaminating genomic DNA. Another
pair of primers, ActRI-3 (5'-GATGAGAAGTCATGGTTCAG
G-3') and ActRI-4 (5'-TATGTTTGGCCTTTGTTGATC-3")
were synthesized and used as nested primers to validate
the internal standard and measuring the regulation of Ac-
tRI mRNA levels in HTR8/SVneo cells. The human β-actin
primers, used as another internal control to normalize
cDNA amount in different samples, are AC1 upstream
and AC2 downstream primers of which sequence are 5'-
GGACCTGACTGACTACCTCATGAA-3' and 5'-GGT-
GGAAGGTGGTCAACACCTAG-3', respectively.
Hormonal treatment
Human recombinant activin-A, inhibin-A and follistatin-
288 were kindly provided by Dr. Parlow at the National
Hormone and Pituitary Program. The HTR8/SVneo cells
were plated in 24-well culture plates in FBS supplemented
RPMI medium. Two days after plating when cells reach
about 70% confluence, the culture medium was replaced
with serum-free RPMI 1640. For dose-response studies,
cells were treated with various doses (0.1 to 30 ng/ml) of
activin-A for 12 hours. For time-course experiments, cells
were cultured in the presence or absence of 10 ng/ml ac-
tivin-A for 1, 3, 6, 12, 24 hours. To determine the interac-
tion between activin and follistatin, cells were treated with
activin-A (10 ng/ml) alone, or activin-A with different
concentrations of follistatin-288 (10, 20, 50, or 100 ng/
ml) for 6 h. Similarly, to examine the effect of inhibin on
basal and activin-A-stimulated ActRI mRNA levels, cells
were treated with Activin-A, inhibin-A, either alone or in
combination for 6 h. There are four wells in each treat-
ment group and each experiment was conducted three
times.
Construction of an internal standard for comparative PCR
Cloning of native ActRI PCR product using primers ActRI-
1 and ActRI-2 was performed by ligating the PCR product
into a pDirect (BD Biosciences Clontech, Palo Alto, CA),
followed by sequencing analysis to confirm the identity.
To construct an internal standard for comparative PCR, a
156 base pair segment was removed from the cloned na-
tive ActRI PCR product by restriction digestion using StyI
and Eco47III (Fig. 1). With the same pair of primers is
used in PCR, the subcloned mutant ActRI template yield-
ed a PCR product 156 base pairs smaller than that from
the native cDNA template.
Total RNA extraction, Reverse transcription and Compet-
itive PCR
Total RNA from HTR-8/SVneo cells was extracted using
the RNaid Kit (Bio/Can Scientific Inc., Mississauga, ON)
following manufacture's suggested procedures. Two µg of
total RNA was used to synthesized cDNA using First
Strand cDNA Synthesis Kit (Amersham Pharmacia Bio-
tech Inc., Oakville, ON) as previously described [9]. cPCR
is similar to PCR except that it includes an internal stand-
ard to monitor the variation between different tubes as
well as among different experiments. In the cPCR reac-
tion, target sequences of native cDNA or sample cDNA
combined with 0.5 pg/µl of the internal standard of ActRI
cDNA (internal standard, IS) are co-amplified in a tube
with a volume of 50 µl containing 5 µl of 10 × PCR buffer
[200 mM Tris-HCl (pH 8.4), 500 mM KCl], 1.5 µl MgCl2
(50 mM), 1 µl dNTPs (10 mM), 0.5 µl Taq DNA polymer-
ase (5 units/µl) (Gibco BRL), 38 µl sterile Milli-Q water, 1
µl each (5 µM) of specific primers (ActRI-3 and ActRI-4)
and equal volume (1 µl) of IS and cDNA sample or nativeReproductive Biology and Endocrinology 2003, 1 http://www.RBEj.com/content/1/1/29
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cDNA. PCR amplifications were performed for 35 cycles
in a Perkin-Elmer/Citus DNA thermal cycler with denatur-
ation at 94°C for 30 seconds, annealing at 53°C for 30
seconds and extension at 72°C for 90 seconds. The final
cycle was followed by a 15 minutes extension step at
72°C. PCR for β-actin was conducted for 25 cycles using
similar conditions as described for ActRI expect that 2 µl
of cDNA samples were used and annealing temperature
was 55°C.
Assessment and quantification of ActRI mRNA levels
After cPCR, 10 µl from each PCR reaction was subjected to
gel electrophoresis and recorded with a negative film. The
intensity of PCR products was determined using a densit-
ometer and expressed as the ratio of ActRI and IS. β-actin
mRNA levels were used to normalize the samples for var-
iation in cDNA concentrations. Statistical significance of
the data was determined by one-way analysis of variance
followed by Scheffe's test. p < 0.05 was considered
significant.
Results
Validation of cPCR
To validate the cPCR for measurement of ActRI mRNA lev-
els, PCR was conducted using a constant amount of IS
(0.5 pg) and an increasing amount of native ActRI cDNA
(0.01, 0.1, 1, 10 pg). As shown in Fig. 2A, the ratio of band
intensity (native ActRI cDNA/IS), measured by densitom-
etry scanning, was nearly linear when plotted as a func-
tion of the amount of native ActRI cDNA in the cPCR
Figure 1
Schematic structure of the ActRI cDNA and primers used in PCR or cPCR. An 156 bp internal deletion has been done 
between the restriction sites Sty I and Eco47 III. Co-amplification of the ActRI native cDNA and mutant cDNA template using 
primer ActRI-1 and primer ActRI-2 resulted in 700 bp and 544 bp PCR product, respectively. Co-amplification of the ActRI 
native cDNA and mutant cDNA template using primer ActRI-3 and primer ActRI-4 resulted in 650 bp and 494 bp PCR prod-
uct, respectively.
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reaction. To control for variation in sample cDNA concen-
trations, β-actin mRNA levels in each sample was also
measured and used to normalize the ActRI mRNA levels.
To validate a semi-quantitative PCR for β-actin, PCR was
first conducted for 20 to 40 cycles. There is a linear rela-
tionship between the amount of PCR product generated
and the number of PCR cycle when PCR was conducted
between 20 to 30 cycles (data not shown) and therefore,
subsequent β-actin PCR was conducted for 25 cycles. In
addition, when different amount of cDNA (from 0.5 to 4
µl) was used in PCR, there is a linear relationship between
the amount of initial cDNA and PCR product (Fig. 2B).
Activin-A stimulated ActRI mRNA expression
The ActRI mRNA level, measured at 12 hours after treat-
ment, was increased in a dose-dependent manner by ac-
tivin-A (Fig. 3). A significant stimulation (P < 0.05) of
ActRI mRNA levels was observed at the dose of 3, 10 and
30 ng/ml. When IEVT cells were treated with activin-A (10
ng/ml) for different period of time, a significant increase
in ActRI mRNA level was found at 3 hours (P < 0.05) and
the maximal response observed at 6 hours (P < 0.01) after
treatment. By 24 h after treatment, ActRI mRNA levels in
activin-A treated cells were not significantly different from
those in the control cells (Fig. 4).
Follistatin blocked the effect of activin-A on ActRI mRNA 
expression
The activin-binding protein, follistatin, has been shown to
neutralize the effects of activin in several biological
Figure 2
Validation of PCR. A) Competitive PCR for ActRI was performed using a constant amount of internal standard (0.5 pg) and 
increasing amount of native ActRI cDNA. A linear relationship was found when the ratio of native ActRI cDNA versus internal 
standard was plotted as a function of the amount of native ActRI cDNA. B) β-actin PCR was conducted using different amount 
of template cDNA. There is a linear relationship between the amount of cDNA used and the amount of PCR product 
generated.
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systems [24–27]. To determine the specificity of activin-A
action, we examined the effects of increasing concentra-
tions of recombinant human follistatin-288 on activin-A-
induced ActRI mRNA levels. Treatment with activin-A
alone resulted in a significant increase in ActRI mRNA lev-
els (P < 0.05); however, when activin-A and follistatin
were added to the culture together, the activin-A-stimulat-
ed ActRI mRNA levels were decreased. At the doses of 50
and 100 ng/ml, follistatin-288 completely blocked the ef-
fects of activin-A on the ActRI mRNA levels (Fig. 5).
Inhibin-A antagonized the effect of activin-A on ActRI 
mRNA expression
Inhibin-A has opposing effects as activin-A in many bio-
logical systems. In this study, we also examined the effect
of inhibin-A on ActRI mRNA levels. Inhibin-A (10 ng/ml)
induced a 60% reduction in ActRI mRNA levels (p < 0.01)
within six hours of treatment. When inhibin-A was ap-
plied together with activin-A (10 ng/ml), significant
reductions in activin-A-stimulated ActRI mRNA levels
were observed (Fig. 6).
Discussion
For many years the placental cytotrophoblasts obtained
by disaggregation of placental tissue have served as the
most widely investigated model for the study of placental
function in vitro. However, the purity of cytotrophoblasts
was not consistent. The IEVT cells used in the study exhibit
similar cellular function to normal EVT cells [21] and they
Figure 3
Dose-dependent stimulation of ActRI mRNA levels by activin-A. Cells were incubated for 12 h in the absence or presence of 
activin-A (0.1–30 ng /ml). cPCR was performed to measure ActRI mRNA levels. The data were pooled from 3 separate exper-
iments and expressed as a percentage of control value (mean ± SEM). Data were normalized for β-actin mRNA levels meas-
ured by PCR. *(p < 0.05) or **(p < 0.01) versus control.
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provide a promising model to study the function of EVT
cells. Using these cells, we have demonstrated that activin-
A stimulates, while inhibin-A inhibits, ActRI mRNA levels.
Our results showed that ActRI mRNA accumulation at 12
hours after treatment was stimulated in a dose-dependent
manner by activin-A. The time course of the activin-A ef-
fect on ActRI mRNA showed responses at 3 to 12 hours af-
ter treatment, with a maximal increase occurring at 6
hours. This response pattern of activin-A on ActRI mRNA
suggests that activin-A exerts a positive feedback effect on
its own receptor and that the action of activin-A on ActRI
mRNA level is transient. The transient effect of activin-A is
likely due to the termination of activin signaling. Activin
signaling has been shown to be terminated by negative
feedback mechanisms involving the activation of Smad7
by activin, and in turn, Smad7 inhibits further activin sig-
naling by blocking the phosphorylation of Smad2/3 by
activin type I receptors [28,29]. In addition, activin signal-
ing can also be terminated by the degradation of Smad
proteins through the ubiquitination pathway [30].
The changes in ActRI mRNA levels as determined by cPCR
in this study could have resulted from changes in the tran-
scriptional rate of ActRI gene and/or the stability of the Ac-
tRI mRNA. Activin is known to regulate gene expression at
the level of transcription via the Smad signaling pathway
[5–7] and expression of Smads in trophoblast cells includ-
ing the HTR8/SVsno have been demonstrated [31,32], it is
therefore possible that activin-A may regulate its receptor
expression at the level of gene transcription. Future
Figure 4
Time course effects of activin-A on ActRI mRNA levels. IEVT cells were incubated with or without activin-A (10 ng/ml) for 1, 
3, 6, 12, 24 hours. cPCR was performed to measure ActRI mRNA levels and data were also normalized for β-actin value. *,(p 
< 0.05) versus control. **,(p < 0.01) vs control. Data present mean ± SEM of three experiments.
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studies are also needed to confirm that there is a correlat-
ed change at the protein level.
Although this is the first study demonstrating that activin-
A regulates its own receptor expression in human placen-
ta, several studies in other tissues have also observed mod-
ulation of activin signaling by activin itself. In the rat
pituitary, activin-A stimulated ActRI and ActRIIB mRNA
levels without altering ActRII mRNA expression [33]. On
the other hand, activin-A downregulated ActRIB, ActRII
and ActRIIB mRNA levels in a cell line derived from a
p53(-/-)inhibin-α (-/-) mouse testicular tumor [34].
Follistatin is widely distributed and produced by many ac-
tivin-responsive tissues [1,25] and may, therefore, serve to
anatomically and temporally limit the local activities of
activin. Follistatin mRNA transcripts and immunoreactiv-
ities have been detected in placental trophoblast cells [16]
Similar to many other systems [24,25], follistatin also
neutralizes activin actions in human placenta [16]. In the
present study, we also found that the stimulatory effect of
activin-A on ActRI mRNA levels could be completely
blocked by follistatin. Since it is known that follistatin in-
hibits activin actions by binding to activin and thus pre-
venting the interaction between activin and its type II
receptor [35] the neutralization of activin-A action on Ac-
tRI mRNA levels by follistatin suggests that the action of
activin is a receptor-mediated event.
Figure 5
Interaction between activin-A and follistatin-288 on ActRI mRNA expression. Cells were incubated for 6 hours in the presence 
or absence of activin-A (10 ng/ml) alone, or activin-A(10 ng/ml) incombination with increasing concentrations of follistatin (10–
100 ng/ml). cPCR was performed to obtain ActRI mRNA levels which were then normalized for β-actin mRNA levels meas-
ured by PCR. Data present mean ± SEM of three experiments. Different letters indicate statistically significant differences (p < 
0.05).
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Inhibin and activin possess opposing activities in several
biological systems including pituitary FSH secretion,
erythroid differentiation, and gonadal sex-steroid
production [4]. In the present study, we found that inhib-
in-A caused a 60 % reduction in basal ActRI mRNA levels
and completely inhibited activin-A-induced ActRI mRNA
expression. This finding is in agreement with the observa-
tion that inhibin counteracts the effects of activin on cul-
tured first trimester trophoblast cells [17].
In summary, we have demonstrated that in activin-A up-
regulates mRNA levels of it own receptor ActRI in human
extravillous trophoblast cells. Since activin-A has been
shown to stimulate the differentiation of extravillous tro-
phoblast cells [14], the up-regulation of ActRI by activin-
A suggests a positive feedback regulatory mechanism by
which activin-A modulates its own signaling in these cells.
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